Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.02) by 2.94 percent. This is a 40 percent increase over losses of $(1.65) per share from
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial release The Stratys instrument can enable up to a four-fold increase in raw data